Technical Analysis for ALLO - Allogene Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 26.1 -0.27% -0.07
ALLO closed down 0.27 percent on Wednesday, June 26, 2019, on 73 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
1 Watcher
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Down
See historical ALLO trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Bollinger Band Squeeze Range Contraction -0.27%
Down 3 Days in a Row Weakness -0.27%
Down 4 Days in a Row Weakness -0.27%

Older signals for ALLO ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
Basic chart:
Profile
Allogene Therapeutics is a clinical stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.
Biotechnology Cancer Life Sciences Stem Cells Cell Biology Therapy Cell Therapy Therapies For Cancer Kite Pharma Adoptive Cell Transfer
Is ALLO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jun 22 Senator Dianne Feinstein’s Husband Sold Nvidia Stock, Bought FireEye
Jun 6 Allogene Therapeutics (ALLO) Investor Presentation - Slideshow
Jun 5 Benzinga's Top Upgrades, Downgrades For June 5, 2019
Jun 4 Allogene Therapeutics Announces FDA Clearance of the IND for ALLO-715, a BCMA Allogeneic CAR T (AlloCAR T™) Therapy
Jun 3 Health Care Digest: Why California biotech thrives, small company looks to crash NASH bash, meeting up at BIO
May 31 Wells Fargo likes Molina after Investor Day
May 29 Allogene Therapeutics Announces June 2019 Investor Conference Schedule
May 11 Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q1 2019 Results - Earnings Call Transcript
May 8 Allogene Therapeutics Inc (ALLO) Q1 2019 Earnings Call Transcript
May 7 Allogene Therapeutics: 1Q Earnings Snapshot
See more ALLO news...
Indicators
Indicator Value
52 Week High 35.55
52 Week Low 21.67
Average Volume 469,101
200-Day Moving Average 0.0
50-Day Moving Average 28.0198
20-Day Moving Average 26.8305
10-Day Moving Average 26.991
Average True Range 1.0833
ADX 12.24
+DI 17.3815
-DI 21.3404
Chandelier Exit (Long, 3 ATRs ) 25.6451
Chandelier Exit (Short, 3 ATRs ) 28.5199
Upper Bollinger Band 28.0668
Lower Bollinger Band 25.5942
Percent B (%b) 0.2
BandWidth 9.215631
MACD Line -0.4043
MACD Signal Line -0.3684
MACD Histogram -0.0359
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 26.91
Resistance 3 (R3) 26.95 26.72 26.78
Resistance 2 (R2) 26.72 26.51 26.70 26.73
Resistance 1 (R1) 26.41 26.39 26.30 26.37 26.68
Pivot Point 26.18 26.18 26.12 26.16 26.18
Support 1 (S1) 25.87 25.97 25.76 25.83 25.52
Support 2 (S2) 25.64 25.85 25.62 25.47
Support 3 (S3) 25.33 25.64 25.43
Support 4 (S4) 25.29